Page 5 - Juergen Eckhardt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LONDON and NEW YORK  , May 12, 2021 /PRNewswire/ -- Huma Therapeutics Limited today announces the completion of its latest funding round with financing of approximately $130 million. The investment will scale Huma's modular platform which can power digital 'hospitals at home' nationally, and support the pharmaceutical and research industries to run the largest ever decentralized clinical trials. Huma's platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research. Leaps by Bayer and Hitachi Ventures led the Series C funding rou...

Huma, which uses AI and biomarkers to monitor patients and for medical research, raises $130M While much of the world eagerly watches to see if the vaccination rollout helps curb and eventually stamp out Covid-19, one of the companies that has been helping to manage the spread of the virus is announcing a big round of funding on the heels for strong demand for its technology. Huma, which combines data from biomarkers with predictive algorithms both to help monitor patients, and uses the same technology to help researchers and pharmaceutical companies run clinical trials, has closed an equity ...

The funds will be used to scale its remote monitoring platform.

Edifice, a Healthcare Disruptor spun out of Stanford, Raises $12 Million to Reinvent Immune Health, Improve Healthspan, and Change Course of Aging News provided by Share this article Share this article SAN MATEO, Calif., April 22, 2021 /PRNewswire/ -- Edifice Health, a Silicon Valley emerging company in immunological health and personalized nutrition, today announced a $12 Million investment, led by Leaps by Bayer. Through its highly-differentiated approach, Edifice aims to harness previously unattainable insights into the root causes of chronic diseases of aging, followed by delivering hig...

Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities Top industry leaders and venture firms unite behind Ukko's efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten News provided by Share this article Share this article PALO ALTO, Calif., TEL AVIV, Israel and LEVERKUSEN, Germany, Jan. 27, 2021 /PRNewswire/ -- Ukko, a biotech company with the mission to eliminate food allergies and sensitivities, today announced $40 million in new Series B funding. Ukko harnesses artificial inte...